Reusable pen injector market to hit $6.73 billion by 2030

The reusable pen injector market is projected to grow from $4.46 billion in 2025 to $4.83 billion in 2026, with long-term demand driven by diabetes, self-administration, and home-based care. The Business Research Company says the market could reach $6.73 billion by 2030 as connected devices, biologics and reusable designs gain traction.

Why it matters: - Reusable pen injectors sit at the center of a broader shift toward patient-friendly drug delivery, especially for chronic diseases that require frequent injections. - The market is expanding as providers and patients look for devices that improve dosing accuracy, support self-administration and reduce medical waste. - Rising diabetes prevalence is a major demand driver because insulin delivery remains one of the largest use cases for pen injectors.

What happened: - The Business Research Company released a market report on the reusable pen injector category on Sept. 14, 2026. - The report says the market grew from $4.46 billion in 2025 to a projected $4.83 billion in 2026. - The report forecasts the market will reach $6.73 billion by 2030. - The company included a free sample link for the report: Download the sample report. - The company also provided the full report here: View the full market report.

The details: - Reusable pen injectors are manually operated devices built for repeated delivery of precise doses of injectable medication. - The devices use replaceable cartridges and detachable needles. - The format is designed to support controlled dosing, easier handling and convenience for long-term therapy. - The devices are used in both clinical and home care settings. - The report says the market grew at an 8.4% CAGR from 2025 to 2026 and is expected to expand at an 8.6% CAGR through 2030. - Growth drivers include higher rates of diabetes and other chronic diseases, new insulin pen systems, wider adoption of self-administration, better healthcare infrastructure and greater focus on dosing accuracy and compliance. - Forecast drivers include smart connected injector ecosystems, home-based healthcare delivery, digital dose tracking and analytics, and growing use of biologics and biosimilar injectable therapies. - The report also points to demand for sustainable reusable devices, ergonomic designs and cartridge-based modular drug delivery systems.

Between the lines: - The market outlook suggests reusable devices are becoming part of a larger effort to combine convenience, adherence and lower waste in drug delivery. - The emphasis on connected features and digital tracking signals that pen injectors are moving beyond basic hardware into data-enabled care tools. - Diabetes remains the clearest commercial anchor, but the broader push into biologics and home care could widen the market beyond insulin use alone. - In August 2023, the International Diabetes Federation said about 11.1% of adults ages 20-79, or 1 in 9 people, were expected to have diabetes in 2025, with more than 40% undiagnosed. - The International Diabetes Federation projected that by 2050 nearly 1 in 8 adults, or about 853 million people, will be affected, a 46% increase.

What's next: - North America held the largest market share in 2025 because of strong healthcare infrastructure and early adoption of advanced drug delivery technology. - Asia-Pacific is expected to be the fastest-growing region over the forecast period, supported by wider healthcare access, rising chronic disease rates and greater awareness of self-administration therapies. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The Business Research Company says its 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

The bottom line: - Reusable pen injectors are moving from a niche delivery option to a broader chronic-care platform, with diabetes demand, home treatment and smart-device features driving the next stage of growth.